umedaptanib pegol (RBM-007) / RIBOMIC 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   0 News 
  • ||||||||||  Review, Journal:  Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology. (Pubmed Central) -  Aug 12, 2023   
    Aptamers used for early detection and treatment of ocular tumors were derived from other disease biomarkers, such as CD71, nucleolin, and high mobility group A. In this review, the development and application of aptamers in eye disorders in recent years are systematically discussed, which may inspire a new link between aptamers and eye disorders. The aptamer development trajectory also facilitates the discovery of the pathogenesis and therapeutic strategies for various eye disorders.
  • ||||||||||  umedaptanib pegol (RBM-007) / RIBOMIC
    Trial completion, Trial completion date, Trial primary completion date:  TEMPURA: RBM-007 in Treatment na (clinicaltrials.gov) -  Aug 25, 2022   
    P1/2,  N=5, Completed, 
    N=22 --> 40 Recruiting --> Completed | Trial completion date: Jul 2022 --> Mar 2022 | Trial primary completion date: Jun 2022 --> Feb 2022
  • ||||||||||  umedaptanib pegol (RBM-007) / RIBOMIC
    Trial completion, Combination therapy, Monotherapy:  TOFU: A Phase II Study of RBM-007 Alone and RBM-007 With Eylea (clinicaltrials.gov) -  Feb 8, 2022   
    P2,  N=86, Completed, 
    Recruiting --> Completed | Trial completion date: Jul 2022 --> Mar 2022 | Trial primary completion date: Jun 2022 --> Feb 2022 Active, not recruiting --> Completed
  • ||||||||||  RBM007 / RIBOMIC
    Review, Journal:  Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer. (Pubmed Central) -  Oct 28, 2021   
    An isolated inhibitory RNA aptamer against FGF2, named RBM-007, has followed an extensive preclinical study, with two clinical trials in phase 2 and phase 1, respectively, underway to assess the therapeutic impact in age-related macular degeneration (wet AMD) and achondroplasia (ACH), respectively. Moreover, showing broad therapeutic potential, preclinical evidence supports the use of RBM-007 in the treatment of lung cancer and cancer pain.
  • ||||||||||  umedaptanib pegol (RBM-007) / RIBOMIC
    Enrollment closed, Combination therapy, Monotherapy:  TOFU: A Phase II Study of RBM-007 Alone and RBM-007 With Eylea (clinicaltrials.gov) -  Aug 11, 2021   
    P2,  N=81, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=40 --> 22 Recruiting --> Active, not recruiting
  • ||||||||||  RBM007 / RIBOMIC
    Preclinical, Journal:  An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice. (Pubmed Central) -  Jul 14, 2021   
    When delivered by subcutaneous injection, RBM-007 restored defective skeletal growth in a mouse model of achondroplasia. We thus demonstrate a ligand-trap concept of targeting the cartilage FGFR3 and delineate a potential therapeutic approach for achondroplasia and other FGFR3-related skeletal dysplasias.
  • ||||||||||  umedaptanib pegol (RBM-007) / RIBOMIC
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy:  TOFU: A Phase II Study of RBM-007 Alone and RBM-007 With Eylea (clinicaltrials.gov) -  Jun 28, 2021   
    P2,  N=81, Recruiting, 
    We thus demonstrate a ligand-trap concept of targeting the cartilage FGFR3 and delineate a potential therapeutic approach for achondroplasia and other FGFR3-related skeletal dysplasias. Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
  • ||||||||||  umedaptanib pegol (RBM-007) / RIBOMIC
    Enrollment open:  TEMPURA: RBM-007 in Treatment na (clinicaltrials.gov) -  Jun 21, 2021   
    P1/2,  N=5, Recruiting, 
    Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021 Not yet recruiting --> Recruiting
  • ||||||||||  umedaptanib pegol (RBM-007) / RIBOMIC
    New P1/2 trial:  TEMPURA: RBM-007 in Treatment na (clinicaltrials.gov) -  May 19, 2021   
    P1/2,  N=5, Not yet recruiting, 
  • ||||||||||  umedaptanib pegol (RBM-007) / RIBOMIC
    Trial completion:  SUSHI: RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (clinicaltrials.gov) -  Jul 5, 2019   
    P1/2,  N=9, Completed, 
    The anti-angiogenic and anti-scarring dual action of RBM-007 holds promise as an additive or alternative therapy to anti-VEGF treatments for nAMD. Recruiting --> Completed